[1]王舒婷,陈海波,施昌盛,等.经皮射频消融联合125I放射性粒子植入术治疗肝恶性肿瘤的疗效分析 [J].介入放射学杂志,2020,29(06):587-590.
 WANG Shuting,CHEN Haibo,SHI Changsheng,et al.Radiofrequency ablation combined with 125I radioactive seed implantation for the treatment of liver cancer: analysis of curative effect[J].journal interventional radiology,2020,29(06):587-590.
点击复制

经皮射频消融联合125I放射性粒子植入术治疗肝恶性肿瘤的疗效分析
()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
29
期数:
2020年06
页码:
587-590
栏目:
非血管介入
出版日期:
2020-06-25

文章信息/Info

Title:
Radiofrequency ablation combined with 125I radioactive seed implantation for the treatment of liver cancer: analysis of curative effect
作者:
王舒婷 陈海波 施昌盛 施振静 虞希祥 孙志超
Author(s):
WANG Shuting CHEN Haibo SHI Changsheng SHI Zhenjing YU Xixiang SUN Zhichao.
Interventional Ward, Department of Medical Imaging, First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine,Hangzhou,Zhejiang Province 310006,China
关键词:
【关键词】 肝恶性肿瘤 经皮射频消融 125I放射性粒子植入术 微创治疗
文献标志码:
A
摘要:
【摘要】 目的 评价经皮射频消融(RFA)与125I放射性粒子植入术联合治疗直径>5 cm的乏血供肝恶性肿瘤的临床效果。方法 回顾分析2013年1月至2016年6月行微创介入治疗的乏血供肝恶性肿瘤患者80例,根据治疗方式分为两组,RFA联合125I放射性粒子植入术(联合治疗组)47例,单纯行TACE(对照组)33例,比较两组的疗效、总生存期(OS)和不良反应。结果 联合治疗组的客观缓解率(ORR,87.2%)及疾病控制率(DCR,95.7%)均高于对照组(ORR 66.7%,DCR 81.8%),差异均有统计学意义(P<0.05);联合治疗组患者1年的生存率(80.9%)高于对照组(75.8%)(P<0.05)。 结论 经皮RFA联合125I放射性粒子植入术对治疗直径>5 cm的乏血供肝恶性肿瘤有较好的临床疗效,可以提高客观缓解率和疾病控制率,延长患者的近中期生存时间。

参考文献/References:

[1] 国家肿瘤微创治疗产业技术创新战略联盟专家委员会,中国医师协会介入医师分会消融治疗专家工作指导委员会,北京医师协会介入医师分会. 影像引导肝脏肿瘤热消融治疗技术临床规范化应用专家共识[J].中华医学杂志, 2017, 97:2420-2424.
[2] Zuo MX, Huang JH. The history of interventional therapy for liver cancer in China[J]. J Intervent Med, 2018, 1:70-76.
[3] Lau WY, Lai ECH. Loco- regional intervention for hepatocellular carcinoma[J]. J Intervent Med, 2019, 2:43- 46.
[4] 沈颖甜, 朱海东,陈 荔,等. 肝内胆管细胞癌诊疗研究进展[J]. 介入放射学杂志, 2018, 27:285-289.
[5] 王 龙,张 勇,王亚运, 等.125I粒子联合经导管动脉化疗栓塞治疗肝细胞肝癌伴门静脉癌栓临床有效性与安全性meta分析[J]. 介入放射学杂志, 2018, 27: 419- 426.
[6] Gao F, Li C, Gu Y, et al. CT-guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: effectiveness and safety in 16 patients[J]. Eur J Radiol, 2013, 82:70-75.
[7] Qu A, Wang H, LI J, et al. Biological effects of 125I seeds radiation on A549 lung cancer cells: G2/M arrest and enhanced cell death[J]. Cancer Invest, 2014, 32: 209-217.
[8] Allard MA, Sebagh M, Ruiz A, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?[J]. J Hepatol, 2015, 63:83- 92.

相似文献/References:

[1]周 慷,魏梦蝶,石海峰,等.术中增强CT及全身麻醉下呼吸控制在特殊部位肝肿瘤射频消融中的应用 [J].介入放射学杂志,2018,27(09):860.
 ZHOU Kang,WEI Mongdie,SHI Haifeng,et al.The application of intraoperative enhanced CT scan and respiratory control under general anesthesia in radiofrequency ablation treatment of hepatic malignant tumors located at special regions[J].journal interventional radiology,2018,27(06):860.
[2]刘冲,何金瞳,李天,等.水隔离技术对降低肝被膜下肿瘤微波消融术后残存的效果评价 [J].介入放射学杂志,2020,29(03):267.
 LIU Chong,HE Jintong,LI Tian,et al.Application of hydrodissection technique in reducing residual tumor tissue of hepatic subcapsular malignancy after microwave ablation and evaluation of its curative effect[J].journal interventional radiology,2020,29(06):267.
[3]翟越,赵 卫,潘文秋,等.TACE联合载药微球治疗肝癌的研究进展[J].介入放射学杂志,2019,28(12):1211.
 ZHAI Yue,ZHAO Wei,PAN Wenqiu,et al.TACE combined with drug- eluting beads for the treatment of hepatocellular carcinoma: recent progress in research[J].journal interventional radiology,2019,28(06):1211.
[4]钱超一,郝伟远,邵国良,等.桡动脉途径对肝癌患者行亚叶酸/5-氟尿嘧啶/奥沙利铂肝动脉持续灌注化疗的临床应用[J].介入放射学杂志,2023,32(05):474.
 QIAN Chaoyi,HAO Weiyuan,SHAO Guoliang,et al.Clinical application of hepatic arterial infusion chemotherapy via radial artery access by using FOLFOX scheme in treating patients with liver cancer[J].journal interventional radiology,2023,32(06):474.
[5]张赛锋,邵国良.小粒径DEB- TACE治疗肝恶性肿瘤22例分析[J].介入放射学杂志,2023,32(07):667.
 ZHANG Saifeng,SHAO Guoliang..Small-sized drug-eluting beads TACE for hepatic malignant tumors: analysis of 22 cases[J].journal interventional radiology,2023,32(06):667.

备注/Memo

备注/Memo:
(收稿日期:2019-12-31)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2020-06-16